Decorti G, Bartoli Klugmann F, Mallardi F, Klugmann S, Benussi B, Grill V, Baldini L
Cancer Lett. 1983 May;19(1):77-83. doi: 10.1016/0304-3835(83)90139-8.
The effect of ICRF 159 on adriamycin (ADR) cardiotoxicity and on total myocardial calcium content was examined in rats. ICRF 159 did not increase the survival time of ADR-treated animals; however the histological findings showed a significant prevention of ADR-induced cardiomyopathy (CMP) by ICRF. The total myocardial calcium content of animals treated with ADR was significantly higher, while no significant difference was seen in animals pretreated with ICRF 159 as compared with controls. As these findings suggested a role of calcium in ADR CMP and in the pharmacological action of ICRF in this disease, we also tested a closely related chelating agent, EDTA. This molecule decreased myocardial calcium levels in ADR-treated animals almost to normal values; however the histological cardiac alterations were not prevented.
研究了ICRF 159对大鼠阿霉素（ADR）心脏毒性及心肌总钙含量的影响。ICRF 159并未延长ADR处理动物的存活时间；然而，组织学结果显示ICRF可显著预防ADR诱导的心肌病（CMP）。ADR处理动物的心肌总钙含量显著更高，而与对照组相比，ICRF 159预处理的动物未观察到显著差异。由于这些发现提示钙在ADR CMP及ICRF对该疾病的药理作用中发挥作用，我们还测试了一种密切相关的螯合剂乙二胺四乙酸（EDTA）。该分子使ADR处理动物的心肌钙水平几乎降至正常；然而，心脏的组织学改变并未得到预防。
